Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$26.59 USD

26.59
1,844,197

-0.52 (-1.92%)

Updated Oct 9, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

by Zacks Equity Research

Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

Alexion Gets Approval for Label Expansion of Soliris in Japan

by Zacks Equity Research

Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy

by Zacks Equity Research

Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.

Alkermes (ALKS) Up 3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi

by Zacks Equity Research

The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.

    Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria

    by Zacks Equity Research

    Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.

    Alnylam (ALNY) Catches Eye: Stock Jumps 10.5%

    by Zacks Equity Research

    Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

    Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher

    by Zacks Equity Research

    Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

    Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

    by Zacks Equity Research

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

    Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

    by Zacks Equity Research

    Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

    Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline

    by Zacks Equity Research

    Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.

    Protalix Finalizes Accelerated Approval Pathway for PRX-102

    by Zacks Equity Research

    Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

    Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

    by Zacks Equity Research

    Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.

    VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints

    by Zacks Equity Research

    VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.

    Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal

    by Zacks Equity Research

    Sarepta (SRPT) expands its footing in the gene therapy field and signs a deal with StrideBio to develop up to eight new treatments.

    Madhu Goel headshot

    BioDelivery (BDSI) Stock Up on Q3 Earnings Beat & Raised View

    by Madhu Goel

    BioDelivery (BDSI) beats earnings and sales expectations in the third quarter of 2019. The company raises its 2019 revenue guidance.

    Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

    by Zacks Equity Research

    Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

    IVERIC bio (ISEE) Q3 Loss Narrows Y/Y, Zimura Advancing Well

    by Zacks Equity Research

    IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.

    Top Ranked Momentum Stocks to Buy for November 13th

    by Zacks Equity Research

    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 13th

    Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

    by Zacks Equity Research

    Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

    Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

    by Zacks Equity Research

    Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

    Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

    by Zacks Equity Research

    Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

    Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

    by Zacks Equity Research

    Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

    Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

    by Zacks Equity Research

    Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

    Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat

    by Zacks Equity Research

    Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.